Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listMEPHENESIN

MEPHENESIN

  • CAS NO.:59-47-2
  • Empirical Formula: C10H14O3
  • Molecular Weight: 182.22
  • MDL number: MFCD00004718
  • EINECS: 200-427-4
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-09 19:38:33
MEPHENESIN Structural

What is MEPHENESIN?

Toxicity

Mephenesin can produce hemolysis leading to hemoglobinuria with intravenous administration of concentrations greater than 10% . As a central nervous system depressant it can also produce paralysis and respiratory depression.

Originator

Tolserol,Squibb,US,1948

The Uses of MEPHENESIN

Mephenesin was used in the study of ligand-based virtual screening and design of antimalarial compounds.

The Uses of MEPHENESIN

muscle relaxant (skeletal)

Indications

Mephenesin was used for the treatment of muscle spasticity in diseases like Parkinson's or Multiple Sclerosis.

Background

Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression . It first entered use in the 1950s.

What are the applications of Application

Mephenesin is a chemical that relaxes muscle cells in vitro

Definition

ChEBI: 1-(2-methylphenyl)glycerol is a glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage. It is an aromatic ether and a glycerol ether. It is functionally related to an o-cresol.

Manufacturing Process

Into an iron or copper reaction vessel having an efficient stirring device and furnished with a refluxing column and condenser, were charged 330 lb of high quality meta-cresol and 150 lb of glycerol, together with 25 lb of sodium acetate to serve as the catalyst in the reaction. The reaction mixture, of this composition, was then heated to 250°C. The water of the reaction distilled off during the heating as the ether formation proceeded, this removal of water from the reaction chamber being promoted by the presence of the excess of phenol, some of which also continued to distill over. Towards the end of the reaction, after about 12 hours, when about 60% of the glycerol had been converted, at which point the reaction slowed down and the distillate was mainly cresol, the batch was cooled and 50 gallons of water were added to it along with 150 lb of xylene. As the result of these additions and the cooling down of the material the batch stratified into an aqueous layer containing unreacted glycerol, polyglycerols and sodium acetate, and a nonaqueous layer containing the ethers that had been formed in the reaction, together with unreacted cresol which remained in the reaction chamber, dissolved in the xylene that had been added to the batch. The aqueous layer was then separated and the water content removed therefrom by evaporation to a degree suitable for the recovery of the glycerol and sodium acetate contents of the layer, for their reuse in the process in a succeeding batch therein. The separated nonaqueous layer containing the ethers was distilled to recover the xylene and cresol contents respectively as the early fractions of the layer thus subjected to distillation. The cresol thus recovered, together with the cresol recovered from the distillate obtained during the heating of the reaction mixture, was returned to the process for reuse in a succeeding batch. Redistillation of the ether mixture recovered is usually necessary and desirable, particularly from the point of view of removing last traces of cresol therefrom. The yield of mixed ethers in this example was about 200 lb, in the relative proportions stated of about 70 parts of monoether to 30 of diether.

brand name

Tolserol (Bristol-Myers Squibb);Bioglan m/q;Decontracyl-baum;Geno-sal;Glykresinum;Glyptol;Kencaps;Mefentil;Mepha-gesic;Mephesol;Midisalb-m;Myocalm;Myolisysin;Neo-xoline-m;Nochyrol;Relaxil-g;Rhex "hobein";Salimed compound;Walconesin.

Therapeutic Function

Muscle relaxant

World Health Organization (WHO)

Mephenesin, a centrally acting muscle relaxant and sedative, was introduced in 1948 and its use has subsequently been associated with some of the undesirable features of barbiturate use. It is of limited efficacy since it is shortacting and does not relieve the spasticity associated with chronic neurological disorders. It has therefore been largely superseded by benzodiazepines but it remains available in some countries.

Pharmacokinetics

Mephenesin reduced neuronal excitability leading to decreases action potentials to muscle fibers which ultimately produces a reduction in spasticity .

Metabolism

Not Available

Properties of MEPHENESIN

Melting point: 69-71 °C(lit.)
Boiling point: 153-154 °C4 mm Hg(lit.)
Density  1.0966 (rough estimate)
refractive index  1.5320 (estimate)
Flash point: 153-154°C/4mm
storage temp.  Sealed in dry,Room Temperature
solubility  Soluble in alcohol
form  Solid
pka 13.52±0.20(Predicted)
color  White
Merck  14,5850

Safety information for MEPHENESIN

Signal word Warning
Pictogram(s)
ghs
Skull and Crossbones
Acute Toxicity
GHS06
GHS Hazard Statements H301:Acute toxicity,oral
Precautionary Statement Codes P264:Wash hands thoroughly after handling.
P264:Wash skin thouroughly after handling.
P270:Do not eat, drink or smoke when using this product.
P321:Specific treatment (see … on this label).
P405:Store locked up.

Computed Descriptors for MEPHENESIN

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.